In recent decades, the epicardial adipose tissue (EAT) has been at the forefront of scientific
research because of its diverse role in the pathogenesis of cardiovascular diseases (CVDs) …

Purpose To systematically evaluate the effect of Sodium-glucose cotransporter 2 (SGLT2)
inhibitors on adipose tissue in patients with type 2 diabetes. Methods We searched PubMed …

Objective We recently demonstrated that treatment with sodium-glucose cotransporter-2
inhibitors (SGLT-2i) leads to an increase in myocardial flow reserve in patients with type 2 …

Aims Degenerative aortic valve stenosis with preserved ejection fraction (ASpEF) and heart
failure with preserved ejection fraction (HFpEF) display intriguing similarities. This study …

Abstract Background Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure (HF)
at high risk for progression to overt disease. Using baseline characteristics of study …

Aims To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose
tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 …

Aim Epicardial adipose tissue (EAT) plays a role in obesity‐related heart failure with
preserved ejection fraction. However, the association of EAT thickness with the development …

Epicardial adipose tissue (EAT) is a fat depot covering the heart. No physical barrier
separates EAT from the myocardium, so EAT can easily affect the underlying cardiac …

Aim Effort intolerance is frequent in patients with overweight/obesity and/or type 2 diabetes
(T2D) free from cardiac and respiratory disease. We sought to quantify the independent …

Obesity condition causes morphological and functional alterations involving the
cardiovascular system. These can represent the substrates for different cardiovascular …